<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316013</url>
  </required_header>
  <id_info>
    <org_study_id>18/044</org_study_id>
    <nct_id>NCT04316013</nct_id>
  </id_info>
  <brief_title>Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial</brief_title>
  <official_title>Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health &amp; Medical Research Council of Australia (NH&amp;MRC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Australian and New Zealand College of Anaesthetists (ANZCA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Victorian Comprehensive Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus&#xD;
      sevoflurane) and lidocaine versus placebo on duration of disease free survival inpatients&#xD;
      with either colorectal or non small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VAPOR-C is a pragmatic, event-driven, randomised controlled trial, with a blinded 2x2&#xD;
      factorial design for sevoflurane/propofol and for intravenous lidocaine/placebo&#xD;
      administration.&#xD;
&#xD;
      This trial is designed to test for superiority in disease free survival (DFS) of propofol&#xD;
      (total intravenous anaehesia -TIVA) over sevoflurane (inhalational volatile anaesthesia) and&#xD;
      intravenous lidocaine over placebo in patients undergoing surgery for colorectal or non small&#xD;
      cell lung cancer (NSCLC). The combination of two cancer types will help address the need to&#xD;
      demonstrate the effects of anaesthetic technique across cancers to inform generalisable&#xD;
      anaesthesia guidelines. Both NSCLC and colorectal cancer are important for this study due to&#xD;
      high incidence rate, many longer-term survivors, and importantly the high risk of local or&#xD;
      distant recurrence despite complete surgical resection. In addition, the study will collect&#xD;
      additional data in a nested cohort related to the exploratory objectives.&#xD;
&#xD;
      The study aims to recruit 5,736 patients in Australia, New Zealand, Canada, United States and&#xD;
      Europe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an event-driven, international multicentre, randomised controlled trial with a 2x2 factorial design. Patients with stage I-III colorectal cancer or stage I-IIIa NSCLC are eligible and will be randomised in the ratio of 1:1:1:1 using permuted block randomisation with stratification by cancer type (Colon, Rectal or NSCLC), preoperative cancer risk stage (Colon: low [stage I &amp; II] and high [stage III] risk; Rectal: low [stage I] and high [stage II &amp; III] risk; NSCLC: low [stage I] and high [stage II &amp; IIIa] risk) and by site to receive either 1) sevoflurane maintenance anaesthesia and lidocaine infusion or 2) sevoflurane maintenance anaesthesia and placebo; or 3), propofol maintenance anaesthesia and lidocaine infusion or 4), propofol maintenance anaesthesia and placebo.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The propofol-TIVA/sevoflurane element of each arm will have a single blind (patient blinded), as the administering anesthesiologist cannot be blinded to allocation. The lidocaine/placebo element of each ARM will be blinded to the patient, and all members of the VAPOR-C research team. The anaesthetic team caring for the patient will not be blinded to the lidocaine/placebo element of the randomisation ARM only.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of disease free survival (DFS) with propofol-TIVA (DFS) versus sevoflurane</measure>
    <time_frame>Until 957 endpoint events are reached, estimated at 4 years from study start</time_frame>
    <description>The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of disease free survival (DFS) with lidocaine compared with placebo</measure>
    <time_frame>Until 957 endpoint events are reached, estimated at 4 years from study start</time_frame>
    <description>The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival (OS) with propofol-TIVA versus sevoflurane</measure>
    <time_frame>Until 957 endpoint events are reached, estimated at 4 years from study start</time_frame>
    <description>The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and at home with propofol-TIVA versus sevoflurane</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival with intravenous lidocaine versus placebo</measure>
    <time_frame>Until 957 endpoint events are reached, estimated at 4 years from study start</time_frame>
    <description>The study will collect endpoint data for each participant on survival status. This will be used to compare overall survival across arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic post surgical pain with intravenous lidocaine versus placebo</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic post surgical pain with intravenous lidocaine versus placebo</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and at home with intravenous lidocaine versus placebo</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Data will be collected at thirty days post surgery regarding date of discharge from hospital and survival status. This is then used to calculate number of days alive and at home (i.e. out of hospital) and compare across arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-operative complications with propofol-TIVA versus sevoflurane</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Short term postoperative morbidity assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading and Comprehensive Complication Index (CCI) .&#xD;
POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades. Assessment of overall morbidity will be captured by the (CCI) , a validated metric for postoperative morbidity ranging from 0 (no complication) to 100 (death) that is designed to differentiate patients having multiple complications from patients having single complications of the same Clavien-Dindo grade.&#xD;
Major organ-specific postoperative complications within 30 days after surgery will be captured, using the recommended definitions published in the consensus statements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-operative complications with intravenous lidocaine versus placebo</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>Short term postoperative morbidity will be assessed by the Post Operative Morbidity Scale (POMS) with Clavien-Dindo severity grading and Comprehensive Complication Index (CCI) .&#xD;
The POMS is an 18-item tool that addresses nine domains of morbidity relevant to the post-surgical patient . The severity in each POMS domain will then be graded according to the Clavien-Dindo Classification on the basis of treatment applied to correct each respective complication , and captures complications within 5 grades. Assessment of overall morbidity will be captured by the (CCI) , a validated metric for postoperative morbidity ranging from 0 (no complication) to 100 (death) that is designed to differentiate patients having multiple complications from patients having single complications of the same Clavien-Dindo grade.&#xD;
Major organ-specific postoperative complications within 30 days after surgery will be captured, using the recommended definitions published in the consensus statements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of functional capacity with propofol-TIVA versus sevoflurane</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Measured by the Duke Activity Status Index (DASI) The DASI is a self-administered questionnaire that measures a patient's functional capacity. Each question has an individual score for YES and a zero score for NO. The sum of the YES replies is entered into a formula to get a rough estimate of a patient's peak oxygen uptake. The higher the sum of YES answers the better higher the oxygen uptake value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of functional capacity with intravenous lidocaine versus placebo</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Measured by the Duke Activity Status Index (DASI) The DASI is a self-administered questionnaire that measures a patient's functional capacity. Each question has an individual score for YES and a zero score for NO. The sum of the YES replies is entered into a formula to get a rough estimate of a patient's peak oxygen uptake. The higher the sum of YES answers the better higher the oxygen uptake value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical frailty with propofol-TIVA versus sevoflurane</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Measured by the Clinical Frailty Scale (CFS). The CFS is a global score ranging from 1 (very fit) to 9 (terminally ill) to reflect the following domains: disability for basic and instrumental activities of daily living, mobility, activity, energy, and disease-related symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical frailty with intravenous lidocaine versus placebo</measure>
    <time_frame>90 days post surgery</time_frame>
    <description>Measured by the Clinical Frailty Scale (CFS). The CFS is a global score ranging from 1 (very fit) to 9 (terminally ill) to reflect the following domains: disability for basic and instrumental activities of daily living, mobility, activity, energy, and disease-related symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of acute postoperative pain propofol-TIVA versus sevoflurane</measure>
    <time_frame>Days 1 - 3 post surgery</time_frame>
    <description>Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of acute postoperative pain intravenous lidocaine versus placebo</measure>
    <time_frame>Days 1 - 3 post surgery</time_frame>
    <description>Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of chronic post surgical pain with propofol-TIVA versus sevoflurane</measure>
    <time_frame>At 90 days and 12 months post surgery</time_frame>
    <description>Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of chronic post surgical pain with propofol-TIVA versus sevoflurane</measure>
    <time_frame>At 90 days and 12 months post surgery</time_frame>
    <description>Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of chronic post surgical pain with intravenous lidocaine versus placebo</measure>
    <time_frame>At 12 months post surgery</time_frame>
    <description>Pain measured using the Brief Pain Inventory Short Form. Patient reported pain on a scale of 0 to 10 where 0 is no pain and 10 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of chronic post surgical pain with intravenous lidocaine versus placebo</measure>
    <time_frame>At 12 months post surgery</time_frame>
    <description>Pain measured using the Neuropathic Pain Questionnaire. Patient reported neuropathic pain on a scale of 0 to 100 where 0 is no pain and 100 is worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of propofol-TIVA versus sevoflurane</measure>
    <time_frame>during surgery until discharge from Post Anaesthetic Care Unit (PACU) or within the first 4 hours of ICU admission</time_frame>
    <description>Toxicities measured using CTCAE V 5 .0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile intravenous lidocaine versus placebo</measure>
    <time_frame>during surgery until discharge from Post Anaesthetic Care Unit (PACU) or within the first 4 hours of ICU admission</time_frame>
    <description>Toxicities measured using CTCAE V 5 .0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication use with propofol-TIVA versus sevoflurane</measure>
    <time_frame>5 days post anaesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medications use with intravenous lidocaine versus placebo</measure>
    <time_frame>5 days post anaesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility with propofol-TIVA versus sevoflurane</measure>
    <time_frame>Through study completion, estimated to be 4 years</time_frame>
    <description>The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility with intravenous lidocaine versus placebo</measure>
    <time_frame>Through study completion, estimated to be 4 years</time_frame>
    <description>The EQ-5D-5L is a standardised instrument for use as a measure of health outcome and is applicable to a wide range of health conditions and treatments. This five item scale covers the following dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with each dimension having five levels (5L). The use of the EQ-5D-5L will enable utility valuations to be estimated for health states experienced</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of return to intended oncological treatment (RIOT) with propofol-TIVA versus sevoflurane</measure>
    <time_frame>8 to 12 weeks post surgery</time_frame>
    <description>Oncological treatment plan post surgery will be collected prior to surgery and data will be collected post surgery regarding return to this intended plan. A comparison will be made between number of participants receiving post surgery oncological treatment as planned pre-surgery and the number of patients deviating from the plan in each arm of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of return to intended oncological treatment (RIOT) with intravenous lidocaine versus placebo</measure>
    <time_frame>8 to 12 weeks post surgery</time_frame>
    <description>Oncological treatment plan post surgery will be collected prior to surgery and data will be collected post surgery regarding return to this intended plan. A comparison will be made between number of participants receiving post surgery oncological treatment as planned pre-surgery and the number of patients deviating from the plan in each arm of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlative studies</measure>
    <time_frame>Through study completion, estimated to be 4 years</time_frame>
    <description>Inflammatory markers - Neutrophil to lymphocyte ratio (NLR), Platelet to lymphocyte ratio (PLR), C-reactive protein (CRP)&#xD;
Circulating tumour deoxyribonucleic acid (ctDNA), DNA/RNA, Circulating tumour cells (CTCs), immune profile using flow cytometry and plasma for cytokines These are exploratory transnational research outcomes levels of these biomarkers will be measured over the course of the study and analysed for correlation the study outcomes.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">5736</enrollment>
  <condition>Colonic Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane + intravenous lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol TIVA + intravenous lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol TIVA + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous anaesthetic used for induction and maintenance of anaesthesia</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Iv</intervention_name>
    <description>1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per adjusted body weight (aBW), to a maximum of 100 kg, actual body weight to be used in patients less than 60kg.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 18 years or older at screening&#xD;
&#xD;
          2. Has provided written informed consent for the trial&#xD;
&#xD;
          3. Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III&#xD;
             colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological&#xD;
             diagnosis. In cases where a histological diagnosis is not possible, suspected&#xD;
             diagnosis through imaging techniques is acceptable.&#xD;
&#xD;
          4. Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3&#xD;
&#xD;
          5. Scheduled to receive elective, surgical resection with curative intent&#xD;
&#xD;
          6. Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay&#xD;
&#xD;
          7. Able to comply with protocol requirements and follow-up procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine&#xD;
&#xD;
          2. Patient with significant liver disease (with elevated International Normalised Ratio&#xD;
             (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score &gt;Class A;&#xD;
&#xD;
          3. Patient at personal or familial risk of malignant hyperthermia&#xD;
&#xD;
          4. Patient with a history of other malignancies within the past 5 years. However,&#xD;
             patients with malignancies managed with curative therapy and considered to be at low&#xD;
             risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma,&#xD;
             malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer, cervical&#xD;
             carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade&#xD;
             prostate and breast cancer) may be included in the study&#xD;
&#xD;
          5. Patient has distant metastases&#xD;
&#xD;
          6. Patient with an actual body weight less than 45kg&#xD;
&#xD;
          7. Patient has an albumin level &lt; 25 g/L&#xD;
&#xD;
          8. Patient has overt clinical heart failure&#xD;
&#xD;
          9. Patients taking the following drugs within 72 hours prior to surgery:&#xD;
&#xD;
        Antibiotics: Clarithromycin, Telithromycin, Azithromycin, Erythromycin, Ciprofloxacin,&#xD;
        Norfloxacin, Levofloxacin, Sparfloxacin, Isoniazid, Roxithromycin, Chloramphenicol&#xD;
        Antidepressants: Fluvoxamine Calcium-channel blockers: Diltiazem, Nifedipine, Verapamil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Riedel, MB.ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernhard Riedel, MB.ChB</last_name>
    <phone>+61385597663</phone>
    <email>bernhard.riedel@petermac.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha McKeown</last_name>
    <phone>+61385596654</phone>
    <email>Sam.McKeown@petermac.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Cata, MD</last_name>
      <phone>713-792-7452</phone>
      <email>jcata@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Suarez</last_name>
      <email>Jsuarez2@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Pillinger</last_name>
      <phone>+612 9515 7461</phone>
      <email>Neil.pillinger@sydney.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlin Kramer</last_name>
      <phone>+612 9515 8789</phone>
      <email>kaitlin.kramer@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bennett</last_name>
      <email>m.bennett@unsw.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Priscilla Marneros</last_name>
      <phone>+612 9382 4726</phone>
      <email>Priscilla.Marneros@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Eley</last_name>
      <email>va_eley@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christine Woods</last_name>
      <email>ChristineA.Woods@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Bourke</last_name>
      <email>Rachel.bourke@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Cottam</last_name>
      <email>Victoria.cottam@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pal Sivalingam</last_name>
      <email>palvannans@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Allison Kearney</last_name>
      <email>Allison.Kearney@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ballarat Base Hospital</name>
      <address>
        <city>Ballarat Central</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Henderson</last_name>
      <phone>+613 5320 4590</phone>
      <email>Greg.Henderson@bhs.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Natasha Brice</last_name>
      <phone>+613 5320 4590</phone>
      <email>natasha.brice@bhs.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Chew</last_name>
      <email>Sue.Chew@easternhealth.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Amy Skiller</last_name>
      <email>amy.skiller@easternhealth.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Sheridan</last_name>
      <phone>+613 8345 6639</phone>
      <email>Nicole.sheridan@wh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Bates</last_name>
      <email>Samantha.bates@wh.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Weinberg</last_name>
      <phone>+613 9496 5000</phone>
      <email>Laurence.Weinberg@austin.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Sofia Sidiropoulos,</last_name>
      <phone>+613 9496 3224</phone>
      <email>Sofia.Sidiropouls@austin.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Riedel</last_name>
      <email>bernhard.riedel@petermac.org</email>
    </contact>
    <contact_backup>
      <last_name>Sam McKewon</last_name>
      <email>sam.mckewon@petermac.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Myles</last_name>
      <phone>+613 9076 2651</phone>
      <email>P.Myles@alfred.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Wallace</last_name>
      <phone>+613 9076 2651</phone>
      <email>s.wallace@alfred.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Goulburn Valley Health</name>
      <address>
        <city>Shepparton</city>
        <state>Victoria</state>
        <zip>3630</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Dunk</last_name>
      <phone>+613 5832 3094</phone>
      <email>Nigel.dunk@gvhealth.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Natasha Pearson</last_name>
      <email>Natasha.pearson@gvhealth.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mansi Khanna</last_name>
      <email>Mansi.Khanna@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Glazov</last_name>
      <email>lucy.glazov@health.wa.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Corcoran</last_name>
      <email>Tomas.Corcoran@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hird</last_name>
      <email>Natalie.Hird@sjog.org.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

